April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Dupixent might face a threat to its lead in dermatitis – but this comes from Pfizer, not Leo.
The $1.1bn that Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will not come cheap. And then there are the Roche payments.
One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.